| Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses YK Chan, SK Wang, CJ Chu, DA Copland, AJ Letizia, H Costa Verdera, ... Science translational medicine 13 (580), eabd3438, 2021 | 159 | 2021 |
| Overcoming innate immune barriers that impede AAV gene therapy vectors M Muhuri, Y Maeda, H Ma, S Ram, KA Fitzgerald, PWL Tai, G Gao The Journal of clinical investigation 131 (1), 2021 | 121 | 2021 |
| EGF hijacks miR-198/FSTL1 wound-healing switch and steers a two-pronged pathway toward metastasis GM Sundaram, HM Ismail, M Bashir, M Muhuri, C Vaz, S Nama, GS Ow, ... Journal of Experimental Medicine 214 (10), 2889-2900, 2017 | 69 | 2017 |
| Durability of transgene expression after rAAV gene therapy M Muhuri, DI Levy, M Schulz, D McCarty, G Gao Molecular Therapy 30 (4), 1364-1380, 2022 | 61 | 2022 |
| Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles A Biscans, J Caiazzi, N McHugh, V Hariharan, M Muhuri, A Khvorova Molecular Therapy 29 (4), 1382-1394, 2021 | 53 | 2021 |
| Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity Y Xiao, M Muhuri, S Li, W Qin, G Xu, L Luo, J Li, AJ Letizia, SK Wang, ... JCI insight 4 (13), 2019 | 36 | 2019 |
| MicroRNA-138 is a prognostic biomarker for triple-negative breast cancer and promotes tumorigenesis via TUSC2 repression S Nama, M Muhuri, F Di Pascale, S Quah, L Aswad, M Fullwood, ... Scientific reports 9 (1), 12718, 2019 | 35 | 2019 |
| Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells M Arjomandnejad, K Sylvia, M Blackwood, T Nixon, Q Tang, M Muhuri, ... Molecular Therapy Methods & Clinical Development 23, 490-506, 2021 | 27 | 2021 |
| Vectored immunotherapeutics for infectious diseases: Can rAAVs be the game changers for fighting transmissible pathogens? W Zhan, M Muhuri, PWL Tai, G Gao Frontiers in immunology 12, 673699, 2021 | 27 | 2021 |
| Novel combinatorial microRNA-binding sites in AAV vectors synergistically diminish antigen presentation and transgene immunity for efficient and stable transduction M Muhuri, W Zhan, Y Maeda, J Li, A Lotun, J Chen, K Sylvia, I Dasgupta, ... Frontiers in Immunology 12, 674242, 2021 | 21 | 2021 |
| C/EBPβ mediates RNA polymerase III-driven transcription of oncomiR-138 in malignant gliomas F Di Pascale, S Nama, M Muhuri, S Quah, HM Ismail, XHD Chan, ... Nucleic Acids Research 46 (1), 336-349, 2018 | 21 | 2018 |
| Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection VN Hariharan, M Shin, CW Chang, D O’Reilly, A Biscans, K Yamada, ... Proceedings of the National Academy of Sciences 120 (11), e2219523120, 2023 | 20 | 2023 |
| Reducing AAV-mediated immune responses and pathology in a subretinal pig model by engineering the vector genome YK Chan, S Wang, A Letizia, Y Chan, E Lim, A Graveline, HC Verdera, ... Molecular Therapy 27 (4), 298-298, 2019 | 7 | 2019 |
| DNA technology: a reference handbook DE Newton Bloomsbury Publishing USA, 2016 | 7 | 2016 |
| Oncolytic virus alphavirus M1: a new and promising weapon to fight cancer M Muhuri, G Gao Human gene therapy 32 (3-4), 136-137, 2021 | 6 | 2021 |
| Is smaller better? Vaccine targeting recombinant receptor-binding domain might hold the key for mass production of effective prophylactics to fight the COVID-19 pandemic M Muhuri, G Gao Signal Transduction and Targeted Therapy 5 (1), 222, 2020 | 4 | 2020 |
| Immunogenicity and toxicity of AAV gene therapy A Bradbury, D Markusic, M Muhuri, L Ou Frontiers in immunology 14, 1227231, 2023 | 2 | 2023 |
| Novel Approaches in Engineering a Multipurpose AAV Vector Genome to Evade Both Innate and Adaptive Immune Responses M Muhuri, J Xie, YK Chan, J Li, Q Su, AJ Letizia, GM Church, PWL Tai, ... MOLECULAR THERAPY 28 (4), 181-181, 2020 | 1 | 2020 |
| How long do the effects of gene therapy based on adeno-associated virus last? A plain language summary T Moroz, M Muhuri, DI Levy, M Schulz, L Woollard, G Gao Future Rare Diseases 4 (1), 2340283, 2024 | | 2024 |
| Use of novel mirna-binding site cassettes for antigen-presenting cell detargeting of transgene expression by raav gene therapy G Gao, P Tai, M Muhuri, W Zhan US Patent App. 18/297,808, 2023 | | 2023 |
GuangPing GaoVerified email at umassmed.edu
